KMO and Alzheimer disease: Chronic oral therapy with JM6, inhibitor of KMO, was demonstrated to rise brain KYNA, due to de novo synthesis of the compound from L‐kynurenine, and to reduce extracellular glutamate in a transgenic mouse model of AD.161